Abstract
Salivary duct carcinoma (SDC) is a rare subtype of salivary gland carcinoma and is considered to be a high-grade aggressive tumor with morphological resemblance to ductal carcinoma of the breast. We present a case of a patient who suffered from metastatic SDC that was positive for human epidermal growth factor receptor-2 (HER-2) and attained complete objective response, as seen on PET-CT after combined treatment with paclitaxel, carboplatin, and trastuzumab.
MeSH terms
-
Antibodies, Monoclonal, Humanized / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Carboplatin / administration & dosage
-
Humans
-
Liver Neoplasms / drug therapy*
-
Liver Neoplasms / metabolism
-
Liver Neoplasms / secondary
-
Male
-
Middle Aged
-
Multimodal Imaging
-
Paclitaxel / administration & dosage
-
Positron-Emission Tomography
-
Receptor, ErbB-2 / metabolism*
-
Salivary Gland Neoplasms / drug therapy*
-
Salivary Gland Neoplasms / metabolism
-
Salivary Gland Neoplasms / pathology
-
Tomography, X-Ray Computed
-
Trastuzumab
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal, Humanized
-
Carboplatin
-
Receptor, ErbB-2
-
Trastuzumab
-
Paclitaxel